FOX04-DRI is a synthetic peptide designed to target and eliminate senescent cells, which are aging or damaged cells that no longer function properly but remain metabolically active, contributing to chronic inflammation and tissue degeneration.
 By disrupting the interaction between the FOXO4 protein and p53—a key regulator of cell death—FOX04-DRI allows p53 to trigger apoptosis (programmed cell death) specifically in senescent cells, while sparing healthy cells.
 This selective clearance helps restore tissue homeostasis and reduces the harmful effects of the senescence-associated secretory phenotype (SASP), which drives inflammation and tissue damage.
Preclinical studies in aged mice have demonstrated that FOX04-DRI can significantly improve physical fitness, increase stamina and endurance, restore fur density, and enhance kidney function.
 It has also shown potential in improving hormonal balance, such as restoring testosterone levels in aged male mice by clearing senescent Leydig cells.
 Additionally, it may support cognitive health by reducing senescent cell burden in the brain, potentially helping to prevent neurodegeneration.
Other reported benefits include improved mitochondrial function, enhanced energy production, reduced tissue fibrosis, and better metabolic health, including support for fat burning and healthier body composition.
 In animal models, FOX04-DRI has been effective in reversing age-related decline in organ function and improving overall vitality.
 The peptide is typically administered via intermittent subcutaneous injections, with dosing protocols suggesting 300–500 mcg daily during dosing weeks, followed by off-weeks to allow for tissue remodeling.
While no human clinical trials have been completed as of 2025, the available preclinical data suggest that FOX04-DRI may offer a promising approach to combating aging-related decline and supporting longevity.
 It is marketed by some clinics as part of anti-aging protocols to improve tissue health, reduce inflammation, and enhance physical performance.
 However, it remains an experimental research compound, and its long-term safety and efficacy in humans have not been established.